Welcome to our dedicated page for Endonovo Therape news (Ticker: ENDV), a resource for investors and traders seeking the latest updates and insights on Endonovo Therape stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Endonovo Therape's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Endonovo Therape's position in the market.
Endonovo Therapeutics Inc. (OTCQB:ENDV) has announced a Letter of Intent to acquire a leading specialty concrete services company in the Southern U.S. The target company reported unaudited 2021 revenues of $47.7 million and an EBITDA of $5.3 million, showcasing significant growth from $9.5 million in 2018. The acquisition price is set at 4X trailing twelve months EBITDA, contingent on a GAAP audit. CEO Alan Collier emphasizes this move aligns with their 'Build Up Strategy', aimed at bolstering Endonovo's financial performance and expanding growth opportunities.
Endonovo Therapeutics, Inc. (OTCQB:ENDV) has appointed NAMSA as strategic advisors to enhance reimbursement strategies for its SofPulse® product. The collaboration aims to accelerate reimbursement and commercialization efforts, leveraging NAMSA's extensive experience in medical device reimbursement across global markets. NAMSA, a leading Contract Research Organization, will aid Endonovo in navigating complex reimbursement landscapes to facilitate market access for SofPulse®, which is FDA-cleared and CE marked for various therapeutic applications.
Endonovo Therapeutics (OTCQB: ENDV) has initiated a $5 million Regulation A+ common stock offering to advance medical reimbursements for its SofPulse® devices. Extensive market research indicates that achieving reimbursement could significantly enhance the device's availability in U.S. hospitals, where it's proposed as a standard of care for surgical pain and edema management. Clinical studies document impressive efficacy, such as a 2.2X reduction in postoperative narcotic use. Current studies at Columbia and Stanford could facilitate reimbursement applications.
Endonovo Therapeutics (OTC-ENDV) has appointed Garry Michael Kann as the Head of Corporate Development to spearhead the company's new strategy for acquiring specialty service providers in the construction industry. Mr. Kann brings over 30 years of experience in corporate finance and M&A, having completed numerous transactions worth over $2 billion. His goal is to find high-margin subcontractors that will enhance Endonovo's revenue and profit margins. CEO Alan Collier expressed confidence in Kann’s capabilities to execute this strategy, which aims to deliver long-term shareholder value.
Endonovo Therapeutics (OTC-ENDV) announced the filing of a Regulation A+ financing to expand its operations, repaying its senior secured Note, and funding research and development. The company has partnered with Dalmore Group, a leading broker-dealer specializing in Reg A+, to facilitate this financing. Dalmore's extensive experience and established relationships in the market position Endonovo favorably for its capital raising needs. CEO Alan Collier expressed optimism about the collaboration with Dalmore, highlighting the advantages of Reg A+ offerings for minimizing shareholder dilution.
Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced on October 12, 2021, progress on its "Build Up Strategy" aimed at acquiring complementary companies in the construction sector. The first Letter of Intent was signed on July 29, 2021, to acquire a business with a 17% annual growth rate and projected revenues of $20 million in 2021. The acquisition is expected to close by December 31, 2021, and the company aims to enhance its medical device offerings alongside this new venture. Endonovo's core product, the SofPulse® device, continues to gain traction in pain management, with ongoing clinical trials.
Endonovo Therapeutics (ENDV) announced the shipment of its SofPulse® tPEMF devices for a Stanford University study on post-operative pain management. The study aims to evaluate the efficacy of SofPulse® in reducing pain and narcotic usage after orthopedic surgeries, concluding in August 2022. Previous studies, including one at Baylor College of Medicine, showed significant reductions in pain and opioid requirements. Endonovo's CEO expressed optimism about the collaboration's potential to position SofPulse® as a standard pain management solution in orthopedic procedures.
Endonovo Therapeutics (OTCQB: ENDV) has launched a new marketing campaign for its FDA-cleared SofPulse® device, which aims to mitigate opioid use post-surgery, exacerbated by COVID-19. With data showing a 70% reduction in opioid requirements and a 50% decrease in post-operative pain, the device has shown its potential in clinical trials. Alan Collier, CEO, emphasizes the device's role in public health by potentially saving lives and reducing hospital costs. The company projects SofPulse® could save hospitals over $5.7 billion annually if adopted broadly in surgeries.